Big pharmaceutical companies are seeing Chinese biotech as the disruptors. Read more at straitstimes.com. Read more at ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

The three major Hong Kong stock indices weakened collectively. By the close, the Hang Seng Index fell 0.08% to 24,162.87, the Tech Index dropped 0.76% to 5,392.19, and the HSCEI declined 0.15% to ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

American pharmaceutical giant Bristol Myers Squibb agreed Monday to pay up to $11.1 billion to partner with Germany’s ...

US factory activity contracted in May for a third consecutive month and a gauge of imports fell to a 16-year low as firms ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...